Health Economist. Professor, Harvard Medical School. Tweets reflect my views alone and not those of any organization I am affiliated with, including MedPAC

Joined April 2014
19 Photos and videos
Replying to @MedicareMeddler
@MedicareMeddler Appreciate the shout out. Love your work, but I interpret this differently. Maybe like @DanMunro
#100policyarticles100days #22. Price Transparency. @Michael_Chernew and friends find only 48% of inpatient and 53% of outpatient insurance contracts rely on DRGs and APCs as the method of payment. Might be the best argument yet, against price caps.... bit.ly/3Sg172f
1
1
1,204
My bigger concern is that payment var complicates ability of transp. to improve competition. I know rules are work in progress, but in my view we aren't there yet because of inherent barriers to shopping for many pops and services. I think worth asking if bang is worth the buck
1
1
407
maybe @Ateevm will weigh in on the prospects of transparency to combat market failures. Promise and Reality of Price Transparency | New England Journal of Medicine
1
97
Agree. Issue extends to health care (quasi-public?). See healthaffairs.org/doi/abs/10… w/@Ateevm. What do we get if we pay more or lose if we pay less. But if market based, we need to address market failures (antitrust, regs, etc). Surprise billing shows how we can mess this up.
A fundamental tension in public-sector comp is whether pay should be determined by the labor market, as it largely is in the private sector, or by a broader and more subjective notion of what public employees "deserve." Great article throughout by @nicholas_bagley
3
752
Congrats to @AmolNavathe, @ben_ippolito and Danielle pierotti on appointments to medpac. Onward and upward. gao.gov/press-release/gao-ma…
3
26
1,631
My term as Medpac chair ended last month. It was an incredible honor to serve with the exceptional staff and commissioners. (I am told I served with 61 of the past 65 commissioners). I have a few broad takeaways
6
7
68
12,559
I hope going forward that the work launched on the complexity of the Medicare program and the challenges that presents to beneficiaries continues.
2
7
734
In summary, I believe strongly in the value of objective evidence to guide policy. No organization is perfect or always correct, but I think MedPac exemplifies the value that non-partisan analysis can bring to policy debate.
1
1
18
1,141
Congrats to @GottliebEcon, @MariaAPolyakova and team on winning the 2026 @NIHCMfoundation research award. gottlieb.ca/papers/DoctorsIn…. I can attest to the impact this has had on my thinking and policy in general.

1
11
3,743
Michael Chernew retweeted
States seeking to lower hospital prices must confront a range of questions, including how regulatory strategies compare to pro-competitive strategies and, if they decide to regulate, whether to cap or set prices. | Forefront @Michael_Chernew and Quincy Martin | @harvardmed, @Harvard_Law healthaffairs.org/content/fo…
1
3
2
747
Michael Chernew retweeted
#NIHCM's March newsletter features an exclusive interview with Anna Zink, Michael Chernew, and Hannah Neprash, exploring the adoption of an AI-enabled clinical service and its impact on heart disease diagnoses.  Read here: bit.ly/NIHCMMar26newsletter #NIHCM #AI @annalzink @Michael_Chernew
1
1
279